IDEXX Launches DR50 Plus Imaging with 25% Lower Radiation and AI Integration
IDEXX launched the ImageVue DR50 Plus digital imaging system with a 17"x17" panel in U.S. and Canada, featuring high-definition diagnostics integrated with AI workflows. The system reduces radiation exposure by up to 25% vs IDEXX’s prior DR50, 60% vs peers, and streamlines imaging capture to consult through telemedicine.
1. IDEXX Expands Cancer Diagnostic Panel to Include Mast Cell Tumors
IDEXX Laboratories announced that its Cancer Dx™ Panel will add canine mast cell tumor detection at no additional cost beginning mid-year 2026 in the U.S. and Canada. Already deployed in more than 5,500 veterinary practices for lymphoma screening, the panel will now address over one-third of all canine cancer cases. Results will be delivered within 2–3 days in the U.S. and 2–4 days in Canada, using the same blood specimen and workflow as existing tests. The expansion leverages a highly sensitive and specific assay that can detect disease up to eight months before clinical signs appear, reinforcing IDEXX’s position as a leading provider of proactive cancer screening in veterinary medicine.
2. Rollout of inVue Dx™ FNA Cytology Enhances In-Clinic Diagnostics
In late Q4 2025, IDEXX began controlled rollout of Fine Needle Aspiration (FNA) cytology on its inVue Dx™ Cellular Analyzer, featuring a slide-free design and expert pathologist review on demand. This in-clinic application enables veterinarians to evaluate skin masses, identify and quantify abnormal cells, and obtain diagnostic answers while pet owners wait. Initial mast cell tumor detection will be followed by additional oncology and non-oncology menu items over time. By reducing reliance on external labs and turnaround times measured in days rather than weeks, the inVue Dx FNA cytology solution is expected to drive increased equipment utilization and recurring revenue from proprietary consumables.
3. Strategic Impact and Market Opportunity
Mast cell tumors rank among the most common cancers in dogs, particularly those aged seven years and older or in high-risk breeds from four years onward. With an estimated 90 percent of veterinary clinics already using in-house imaging or lab services, IDEXX’s integrated diagnostic offerings present a cross-sell opportunity to its installed base of approximately 11,000 clinics globally. As a member of the S&P 500, IDEXX stands to benefit from accelerated adoption of its expanded Cancer Dx Panel and inVue Dx FNA cytology, contributing to recurring lab revenue growth and strengthening its competitive moat in the $5 billion-plus veterinary diagnostics market.